海吉亚医疗控股有限公司是一家主要提供医疗服务的投资控股公司。该公司通过两个业务部门开展业 务。医院业务分部从事提供肿瘤一站式综合诊疗服务，围绕肿瘤核心业务开展多学科医疗服务，包括提 供医疗放疗、化疗、手术、靶向在内的多重肿瘤医疗服务，逐步覆盖癌症诊断、治疗与康复等各阶段。 其它业务分部主要从事其他业务。该公司主要在国内市场经营其业务。 证券之星消息，2月23日南向资金增持70.0万股海吉亚医疗（06078.HK）。近5个交易日中，获南向资金 减持的有3天，累计净减持226.46万股。近20个交易日中，获南向资金减持的有11天，累计净减持345.14 万股。截至目前，南向资金持有海吉亚医疗（06078.HK）2.01亿股，占公司已发行普通股的32.48%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

证券简称：新里程 证券代码：002219 公告编号：2026-016 新里程健康科技集团股份有限公司 为便于办理相关手续，董事会授权公司经营层在借款额度范围内代表公司办理相关手续，并签署相关法 律文件。 表决结果：11票同意，0票反对，0票弃权。 第七届董事会第四次会议决议公告 二、备查文件 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导性陈述或者重大遗漏。 新里程健康科技集团股份有限公司（以下简称"新里程"或"公司"）第七届董事会第四次会议通知于2026 年2月13日以书面、邮件及电话等形式发出，会议于2026年2月14日在公司会议室以通讯方式召开，本次 会议因情况特殊，经全体董事一致同意豁免通知时限要求。会议由董事长林杨林先生召集并主持，公司 现任董事11名，实际表决董事11名，公司高级管理人员列席本次会议，会议的召开与表决程序符合《中 华人民共和国公司法》和《公司章程》的有关规定，所做决议合法有效。 一、董事会会议审议情况 经与会董事充分讨论，审议通过了以下议案并形成决议。 （一）审议通过《关于公司向银行申请流动资金借款的议案》 因公司经营发展需要，同意公司向甘肃银行股份有限公司 ...

分组1 - GeneDx Holdings Corp. reported quarterly earnings of $0.14 per share, exceeding the Zacks Consensus Estimate of $0.11 per share, and showing a year-over-year decrease from $0.7 per share [1] - The company achieved revenues of $120.99 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.50% and increasing from $95.64 million year-over-year [2] - GeneDx Holdings has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - The stock has underperformed, losing approximately 36.9% since the beginning of the year, while the S&P 500 has gained 0.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $115.8 million, and for the current fiscal year, it is $0.58 on revenues of $526.5 million [7] - The Medical Services industry, to which GeneDx belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, which may impact stock performance [8]

Investment Rating - The industry investment rating is "Positive" (maintained) [5][41]. Core Insights - The medical services and pharmacy sectors have undergone significant adjustments since 2021, with valuations and performance returning to historically low levels. For instance, leading companies like Aier Eye Hospital, Tongce Medical, and Yifeng Pharmacy have seen their total market values decline by 73.5%, 81.9%, and 45.9% respectively since the Spring Festival of 2021 [1][16]. - The consumer medical industry is experiencing an improvement in competition and safety margins, aided by the implementation of relevant policies and a potential recovery in consumer willingness to spend [2]. - The offline pharmacy sector is benefiting from policy incentives and an improved competitive landscape, with significant support for prescription outflow and industry restructuring [3][32]. Summary by Sections 1. Valuation Bottoming and Low Holdings - The medical services and pharmacy sectors have faced prolonged adjustments, leading to valuations at historically low levels. The public fund holdings in these sectors have also decreased [10][11]. - The leading companies in the industry have seen substantial market value adjustments, indicating a low public fund holding ratio [16]. 2. Accumulating Reversal Momentum - The medical services and pharmacy sectors are expected to experience a dual recovery in performance and valuation, driven by improved competition and policy clarity [21]. - The medical services sector is witnessing a gradual recovery in income growth, particularly in the ophthalmology sector, which has seen a slowdown in revenue growth after a rapid recovery period [22]. - The pharmacy sector is experiencing a shift towards health service platforms, supported by policy changes that encourage pharmacies to expand their service offerings [33]. 3. Investment Views - Focus on leading companies in the medical services sector that have strong chain expansion capabilities and supply chain advantages, such as Aier Eye Hospital and Tongce Medical, which are expected to benefit from consumer upgrades and market demand [4][37]. - In the pharmacy sector, attention should be given to leading chains with strong supply chain advantages and management capabilities, such as Yifeng Pharmacy and Dazhenglin, which are well-positioned to capture market share and benefit from policy changes [4][37].

北京商报讯（记者 丁宁）2月23日晚间，通策医疗（600763）发布公告称，2月13日，公司董事长王毅 通过上交所交易系统以集中竞价交易方式增持公司股份1.05万股，增持金额49.96万元；董事黄浴华通过 上交所交易系统以集中竞价交易方式增持公司股份1万股，增持金额47.61万元；董秘张华通过上交所交 易系统以集中竞价交易方式增持公司股份1万股，增持金额47.33万元；其他管理人员赵敏通过上交所交 易系统以集中竞价交易方式增持公司股份7700股，增持金额36.71万元。 此外，公司董事、高管拟自本次增持之日起6个月内，以自有资金或自筹资金通过上交所交易系统以集 中竞价交易方式增持公司股份合计不低于600万元，不超过1200万元，本次增持未设置价格区间。将根 据公司股票价格波动情况及资本市场整体趋势，择机实施增持计划。 ...

格隆汇2月23日｜通策医疗(600763.SH)公告称，公司董事长王毅、董事黄浴华、董秘张华、财务总监徐 国喜、其他管理人员赵敏计划自本次增持之日起6个月内，以自有资金或自筹资金通过上海证券交易所 交易系统以集中竞价交易方式增持公司股份合计不低于600万元，不超过1200万元。本次增持未设置价 格区间。增持主体基于对公司未来持续发展的信心和对公司长期投资价值的认可。 ...

公司董事、高管拟自本次增持之日起6个月内，以自有资金或自筹资金通过上海证券交易所交易系统以 集中竞价交易方式增持公司股份合计不低于600万元，不超过1200万元，本次增持未设置价格区间。将 根据公司股票价格波动情况及资本市场整体趋势，择机实施增持计划。 格隆汇2月23日丨通策医疗(600763.SH)公布，2026年2月13日，董事长王毅通过上海证券交易所交易系 统以集中竞价交易方式增持公司股份10,500股，增持金额499,600元；董事黄浴华通过上海证券交易所交 易系统以集中竞价交易方式增持公司股份10,000股，增持金额476,050元；董秘张华通过上海证券交易所 交易系统以集中竞价交易方式增持公司股份10,000股，增持金额473,310元；其他管理人员赵敏女士通过 上海证券交易所交易系统以集中竞价交易方式增持公司股份7,700股，增持金额367,101元。 ...

公司董事、高管拟自本次增持之日起6个月内，以自有资金或自筹资金通过上海证券交易所交易系统以 集中竞价交易方式增持公司股份合计不低于600万元，不超过1200万元，本次增持未设置价格区间。将 根据公司股票价格波动情况及资本市场整体趋势，择机实施增持计划。 智通财经APP讯，通策医疗(600763.SH)发布公告。2026年2月13日，董事长王毅女士通过上海证券交易 所交易系统以集中竞价交易方式增持公司股份1.05万股，增持金额49.96万元;董事黄浴华女士通过上海 证券交易所交易系统以集中竞价交易方式增持公司股份1万股，增持金额476,050元;董秘张华先生通过 上海证券交易所交易系统以集中竞价交易方式增持公司股份1万股，增持金额473,310元;其他管理人员 赵敏女士通过上海证券交易所交易系统以集中竞价交易方式增持公司股份7700股，增持金额367,101 元。 ...

在外部赋能层面，麦迪卫康将近年来积累的技术探索成果进行了战略迭代与转化，如今公司的技术路线 已全面迭代升级为"AI小模型+区块链"的双轮驱动方向。依托自主研发的"长颈鹿"系列数智平台，麦迪 卫康利用AI小模型对海量医学数据进行深度学习与结构化处理，并结合区块链技术保障数据真实与确 权，成功获得数据服务商证书。这一系列战略布局，不仅高效开拓了医疗数据与医学内容的价值转化新 路径，还为医生提供了更精准的学术支持工具，为药械企业提供了更具穿透力的价值服务。 此次战略升级，标志着公司正从以往的"医疗市场解决方案提供商"，全面升级为"医疗行业AI小模型+区 块链"的技术企业。展望未来，麦迪卫康将继续深化在AI小模型与前沿技术领域的布局，引领医疗服务 行业向智能化、精准化迈进，持续为行业创造增量价值。 回顾内部运营层面，麦迪卫康积极引入智能技术，通过AI小模型工具深度重构业务流程，显著优化人 员结构，提升组织运营效率，使核心团队能够更专注于高价值的策略制定与医学创意，为业务的持续扩 展奠定了坚实的效能基础。 自2021年登陆港交所主板以来，麦迪卫康(02159)持续深耕医疗健康核心领域。随着医疗行业从高速增 长迈向高质量 ...

Investment Rating - The report maintains a positive outlook on the blood products industry, suggesting that the sector has clear long-term growth potential due to increasing supply and demand elasticity [12][19][36]. Core Insights - The blood products industry is expected to benefit from a more relaxed approval process for plasma collection stations during the 14th Five-Year Plan, leading to increased production capacity and a diverse range of products [12][19]. - The report highlights a significant shift in the industry from a supply surplus to a supply-demand balance, with expectations for improved performance in 2026 as supply constraints tighten and demand remains stable [36][34]. - Key companies to watch include TianTan Biotech, BoYa Bio, and HuaLan Bio, which are expected to see performance improvements as the market stabilizes [12][36]. Summary by Sections Market Review - The report notes that the CITIC pharmaceutical index fell by 0.85%, underperforming the CSI 300 index by 1.22 percentage points, ranking 21st among 30 primary industries [6]. - The top-performing stocks in the sector included AidiTe and ZhenDe Medical, while stocks like BeiXin Life and HuaYuan Bio faced significant declines [6][12]. Industry and Stock Events - The blood products sector has experienced a prolonged adjustment period, with a cumulative decline of 18.1% since early 2025, significantly underperforming the broader pharmaceutical sector [16]. - The report indicates that the performance of major blood product companies has varied, with some like WeiGuang Bio and HuaLan Bio performing better than the sector average [16]. Overall Perspective and Investment Themes - The report emphasizes the transition from a quantity-driven to a quality-driven approach in the innovative drug sector, suggesting a focus on differentiated products and international expansion [10]. - In the medical device sector, there is a notable recovery in bidding volumes for imaging equipment, with companies like MaiRui and LianYing expected to benefit from ongoing upgrades [10]. - The report also highlights the importance of the CXO and life sciences services sectors, predicting a recovery in domestic investment and a return to high growth rates [10]. Blood Products - The blood products industry is characterized by a clear growth trajectory, with both supply and demand expected to show significant elasticity [12][19]. - The report suggests that the industry will see improved performance due to a combination of increased plasma collection and a tightening supply situation, which is expected to stabilize prices and enhance profitability for key players [36][34].